In January 2026, MEDIPOST Inc., the U.S. affiliate of South Korea‑based regenerative medicine and biotechnology company MEDIPOST Co., Ltd., successfully closed a $140 million funding round aimed at accelerating late-stage clinical development and operational growth. This capital infusion was led by Skylake Equity Partners and Crescendo Equity Partners, with participation from a leading Korean growth equity fund. The funds are intended to support MEDIPOST’s anticipated Phase III clinical trial of its allogeneic, umbilical cord blood-derived mesenchymal stem cell therapy for symptomatic cartilage defects in knee osteoarthritis, as well as expansion of its scientific, manufacturing, and infrastructure capabilities. [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
History of Cord Blood and Tissue Banking: Landmark Events and Pivotal Trends
The global cord blood industry came into existence in the early 1990’s with the formation of several leading cord blood banks in the USA, followed by the establishment of cord blood banks across the globe. However, the history of cord blood stem cell transplantation begins much earlier than that. [Read more…]
Global Trends in Cord Blood and Newborn Stem Cell Banking
Today, nearly 80% of the global cord blood market is controlled by the world’s 12 largest cord blood banking operators. This is an incredible figure, given that the the cord blood industry grew to over 400 market participants in the early 2000’s but has consolidated dramatically since that time. [Read more…]
The Remarkable Rise of iPSC-derived MSC Therapeutics: iMSCs
The rise of iPSC-derived mesenchymal stem cells (iMSCs) represents a significant evolution in regenerative medicine. iMSCs are generated by reprogramming adult somatic cells, typically fibroblasts, into induced pluripotent stem cells (iPSCs), which are then differentiated into mesenchymal stem cells (MSCs). This breakthrough technology offers several advantages over traditional MSC therapies, which are often derived from limited, patient-specific sources such as bone marrow or adipose tissue. [Read more…]
The Cord Blood Banking Price War is Getting Fierce – and Consumers Are Benefiting
The cost of cord blood banking is extremely affordable due to heated competition. Families now have more options to choose from than ever before.
Cord blood banking is becoming an increasingly common practice. More and more, new parents are becoming aware of the benefits of storing their newborn’s umbilical cord blood – a rich source of stem cells that can be used for life-saving medical treatment in the future. However, the biggest barrier for many families, has been the price.
Cord blood banks have been in a stem cell banking price war, and fortunately, it has made storage more affordable. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 62
- Next Page »